354 related articles for article (PubMed ID: 25660252)
1. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study.
Kim SC; Kim MS; Sanfélix-Gimeno G; Song HJ; Liu J; Hurtado I; Peiró S; Lee J; Choi NK; Park BJ; Avorn J
Am J Med; 2015 May; 128(5):519-26.e1. PubMed ID: 25660252
[TBL] [Abstract][Full Text] [Related]
2. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate use and subsequent hip fracture in South Korea.
Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
5. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
[TBL] [Abstract][Full Text] [Related]
6. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
[TBL] [Abstract][Full Text] [Related]
7. [Hip Fracture--Epidemiology, Management and Liaison Service. Prevention of the secondary hip fractures utilizing the regional post-referral treatment plan].
Matsushita M
Clin Calcium; 2015 Apr; 25(4):545-50. PubMed ID: 25814015
[TBL] [Abstract][Full Text] [Related]
8. Antiresorptive treatment, when initiated after a first hip fracture, may not protect of a second contralateral episode in elderly population: A study with 685 patients.
Besalduch M; Carrera I; Gómez-Masdeu M; De Caso J
Injury; 2016 Apr; 47(4):877-80. PubMed ID: 26892501
[TBL] [Abstract][Full Text] [Related]
9. Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.
Gonnelli S; Caffarelli C; Iolascon G; Bertoldo F; Letizia Mauro G; Patti A; Nuti R
Aging Clin Exp Res; 2017 Oct; 29(5):1031-1037. PubMed ID: 27943127
[TBL] [Abstract][Full Text] [Related]
10. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
[TBL] [Abstract][Full Text] [Related]
11. Incidence of second hip fracture and compliant use of bisphosphonate.
Lee YK; Ha YC; Yoon BH; Koo KH
Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
[TBL] [Abstract][Full Text] [Related]
12. Low rates of osteoporosis treatment after hospitalization for hip fracture in Hawaii.
Nguyen ET; Posas-Mendoza T; Siu AM; Ahn HJ; Choi SY; Lim SY
Osteoporos Int; 2018 Aug; 29(8):1827-1832. PubMed ID: 29744567
[TBL] [Abstract][Full Text] [Related]
13. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
[TBL] [Abstract][Full Text] [Related]
14. Orthopedic-Metabolic Collaborative Management for Osteoporotic Hip Fracture.
Rotman-Pikielny P; Frankel M; Lebanon OT; Yaacobi E; Tamar M; Netzer D; Nabriski D; Nyska M; Brin YS
Endocr Pract; 2018 Aug; 24(8):718-725. PubMed ID: 30084682
[TBL] [Abstract][Full Text] [Related]
15. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
16. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
17. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
18. [Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
Naranjo A; Ojeda-Bruno S; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Rodríguez-Lozano C
Med Clin (Barc); 2011 Mar; 136(7):290-2. PubMed ID: 21185575
[TBL] [Abstract][Full Text] [Related]
19. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
[TBL] [Abstract][Full Text] [Related]
20. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
